The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs
Open Access
- 10 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (11) , 2076-2084
Abstract
Objective. When treating RA patients, remission (REM) or at least low disease activity (LDA) is the ultimate therapeutic goal. The aim of this study was to assess the impact of multimorbidity on achieving REM or LDA. Methods. In a prospective RA cohort, we identified patients initiating any DMARD with follow-up data 1 year after. Treatment effects were measured using the clinical disease activity index (CDAI) and the modified health assessment questionnaire (MHAQ); multimorbidity status was assessed using a counted multimorbidity index (cMMI). The proportion of patients reaching REM or LDA 1 year after DMARD commencement with respect to the cMMI was evaluated. In regression models, we calculated the odds ratio of achieving REM or LDA, and predicted CDAI and MHAQ 1 year after DMARD commencement for various levels of cMMI, adjusting for age, sex, disease duration, serostatus, disease activity at DMARD commencement, number of previous DMARDs, and type of DMARD, steroid and NSAID use. Results. A total of 815 patients started DMARDs; 414 were on the same DMARD after 1 year. The proportion of these patients achieving REM or LDA after 1 year was significantly lower in the patients with higher cMMI, following a linear trend (P < 0.01). After accounting for covariates, the odds ratio for REM associated with each additional morbidity in the cMMI was 0.72 (95% CI 0.55, 0.97) and 0.81 (95% CI 0.70, 0.94) for LDA. One year after DMARD initiation, CDAI (+0.16 per additional morbidity) and MHAQ scores (+0.15 per additional morbidity) were significantly worse (both P < 0.05). Conclusion. Increased multimorbidity negatively affects the therapeutic goal of REM and LDA.Keywords
This publication has 18 references indexed in Scilit:
- A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcomeRheumatology, 2012
- Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitionsAnnals of the Rheumatic Diseases, 2012
- Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritisRheumatology, 2010
- Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential StudyRheumatology, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- Impact of comorbidity on physical function in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Comorbidities in rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2007
- Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidityMusculoskeletal Care, 2007
- Identification of work disability in rheumatoid arthritis: Physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variablesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987